REG - Uniphar PLC - Currency Change on LSE

Stifel FinancialAnnouncement

20/01/2021 10:05

RNS Number : 2317M
  
Uniphar PLC
  
20 January 2021
  
 

 
Uniphar plc Currency Change on London Stock Exchange
 
 
 
Dublin, London | 20 January 2021: Uniphar plc ("Uniphar" or the "Company") today announces it has applied to the London Stock Exchange to change the currency in which the Company's ordinary shares are traded on the London Stock Exchange from Euro to Sterling. It is expected this change will become effective at 8.00 am on 1 February 2021.
 

The currency in which Uniphar's ordinary shares are traded on Euronext Dublin will remain Euro. The Company's financial statements will continue to be presented in Euro.
 


For further details contact:
 




Uniphar


+353 (0) 1 428 7777




 


 




Brian O'Shaughnessy


 




Group Director of Corporate Development


investor.relations@Uniphar.ie




 


 




Davy


+353 (0) 1 679 6363




(Joint Corporate Broker, Nominated Adviser and Euronext
Growth Adviser)


 




 


 




Fergal Meegan


 




Barry Murphy


 




Orla Cowzer


 




 


 




RBC Capital Markets (Joint Corporate Broker)


+44 (0) 20 7653 4000




 


 




Darrell Uden


 




Jonathan Hardy


 




Jamil Miah


 




 


 




Stifel Nicolaus Europe Limited (Joint Corporate Broker)


+44 (0) 20 7710 7600




Matt Blawat


 




Ben Madison


 




Francis North


 




 


 




Q4 PR


+353 (0) 1 475 1444 or




(Public Relations Adviser to Uniphar)


+353 87 235 6461




 


 




Iarla Mongey


 




 
 
About Uniphar plc 
 
Headquartered in Dublin, Ireland, Uniphar plc ("Uniphar" and together with its subsidiaries the "Group") is an international diversified healthcare services business, servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. 
 
The Group has strong established relationships with 7 of the top 10 pharma companies and 6 of the top 10 medical device companies. With a workforce of more than 2,500, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US, delivering unlicensed and specialty medicine on a global basis. 
 
The Group's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability. 
 
Commercial & Clinical 
In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux, and the Nordics, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.
 
Product Access 
In Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.
 
Supply Chain & Retail 
Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCSFUFAUEFSELF